UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000013264
Receipt number R000015472
Scientific Title Study for serum estrogen concentration during aromatase inhibitor treatment
Date of disclosure of the study information 2014/02/25
Last modified on 2016/08/28 09:06:36

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Study for serum estrogen concentration during aromatase inhibitor treatment

Acronym

Serum E2 study

Scientific Title

Study for serum estrogen concentration during aromatase inhibitor treatment

Scientific Title:Acronym

Serum E2 study

Region

Japan


Condition

Condition

Breast Cancer

Classification by specialty

Hematology and clinical oncology Breast surgery

Classification by malignancy

Malignancy

Genomic information

YES


Objectives

Narrative objectives1

This study was designed to investigate intra-patient or inter-patients variability of serum E2 level during aromatase inhibitor treatments.

Basic objectives2

Pharmacodynamics

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Serum E2 level on aromatase inhibitor

Key secondary outcomes



Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit


Not applicable

Age-upper limit


Not applicable

Gender

Female

Key inclusion criteria

Breast cancer patients treated with AI as adjuvant therapy

Key exclusion criteria

Concurrent endocrine treatment other than AI

Target sample size

50


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Hiroshi Ishiguro

Organization

Graduate School of Medicine Kyoto University

Division name

Department of Target Therapy Oncology

Zip code


Address

54 Syogoinkawahara-cho, Sakyo-ku, Kyoto-city

TEL

075-751-4950

Email

hkkishi@kuhp.kyoto-u.ac.jp


Public contact

Name of contact person

1st name
Middle name
Last name Moe Tsuda

Organization

Graduate School of Medicine Kyoto University

Division name

Department of Breast Surgery

Zip code


Address

54 Syogoinkawahara-cho, Sakyo-ku, Kyoto-city

TEL

075-751-3660

Homepage URL


Email

moe1985@kuhp.kyoto-u.ac.jp


Sponsor or person

Institute

Graduate School of Medicine Kyoto University

Institute

Department

Personal name



Funding Source

Organization

Japan's Ministry of Education, Culture, Sports, Science and Technology

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

YES

Study ID_1

G-629

Org. issuing International ID_1

Kyoto University Hospital

Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2014 Year 02 Month 25 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Enrolling by invitation

Date of protocol fixation

2014 Year 02 Month 07 Day

Date of IRB


Anticipated trial start date

2014 Year 02 Month 26 Day

Last follow-up date


Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information

Measure serum E2 level after initiation of AI for at least 4 weeks. Interval between the measure meant is at least 2 months.


Management information

Registered date

2014 Year 02 Month 25 Day

Last modified on

2016 Year 08 Month 28 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000015472


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name